These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 339449)

  • 1. A fluorigenic substrate for the rapid differentiation of Mycobacterium fortuitum from Mycobacterium chelonei on the basis of heat stable esterase activity.
    Grange JM
    Tubercle; 1977 Sep; 58(3):147-50. PubMed ID: 339449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical characterization of Tween 80-hydrolyzing esterases produced by rapidly growing mycobacteria.
    Tomioka H; Yoneyama T; Asano K; Watanabe T; Saito H
    Microbiol Immunol; 1983; 27(8):673-81. PubMed ID: 6645984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the API ZYM system in the identification of Mycobacterium fortuitum and Mycobacterium chelonei.
    García-Rodriguez JA; Gómez-García AC; Iglesias-García J; Martín-Luengo F
    Tubercle; 1982 Sep; 63(3):209-11. PubMed ID: 6758254
    [No Abstract]   [Full Text] [Related]  

  • 4. Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility.
    Collins CH; Yates MD; Uttley AH
    J Hyg (Lond); 1985 Dec; 95(3):619-21. PubMed ID: 2936800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterium chelonei.
    Grange JM
    Tubercle; 1981 Dec; 62(4):273-6. PubMed ID: 7336476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ; Jones DB; Wiss K
    Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of Nontuberculous Mycobacteria from the Environment of Ghanian Communities Where Buruli Ulcer Is Endemic.
    Aboagye SY; Danso E; Ampah KA; Nakobu Z; Asare P; Otchere ID; Röltgen K; Yirenya-Tawiah D; Yeboah-Manu D
    Appl Environ Microbiol; 2016 Jul; 82(14):4320-4329. PubMed ID: 27208141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple, new test for rapid differentiation of the Mycobacterium fortuitum complex.
    Casal MJ; Rodriguez FC
    J Clin Microbiol; 1981 May; 13(5):989-990. PubMed ID: 7240405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorimetric assay of mycobacterial group-specific hydrolase enzymes.
    Grange JM
    J Clin Pathol; 1978 Apr; 31(4):378-81. PubMed ID: 641210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoenzymes as tools to discriminate various subdivisions in the Mycobacterium fortuitum complex.
    Blom-Potar MC; David HL; Rastogi N
    Acta Leprol; 1989; 7 Suppl 1():39-43. PubMed ID: 2548363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gas chromatographic fatty acid determination to differentiate Nocardia asteroides, Mycobacterium fortuitum and Mycobacterium chelonei.
    Fourche J; Capdepuy M; Texier-Maugein J
    J Chromatogr; 1989 Jan; 487(1):142-6. PubMed ID: 2654156
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential identification of Mycobacterium fortuitum and Mycobacterium chelonei.
    David HL; Traore I; Feuillet A
    J Clin Microbiol; 1981 Jan; 13(1):6-9. PubMed ID: 6780604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth of group IV mycobacteria on medium containing various saturated and unsaturated fatty acids.
    Saito H; Tomioka H; Yoneyama T
    Antimicrob Agents Chemother; 1984 Aug; 26(2):164-9. PubMed ID: 6486760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
    Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
    Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic and immunological characterization of the Mycobacterium fortuitum complex.
    Binko BP; Bartholomew WR
    J Clin Microbiol; 1978 Aug; 8(2):246-51. PubMed ID: 100510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frequency and clinical relevance of rapidly growing mycobacterium isolated from respiratory samples].
    Duan HF; Wang QF; Wang J; Wang J; Huang HR; Chu NH
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):113-6. PubMed ID: 26879615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification of clinically important strains of Mycobacterium fortuitum complex].
    Sosnovskaia AV
    Probl Tuberk; 1989; (10):40-3. PubMed ID: 2687843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapidly Growing Mycobacteria.
    Brown-Elliott BA; Philley JV
    Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28084211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.